MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma has informed the exchanges that its insider trading window will be closed from April 1, 2026 until 48 hours after the company declares its audited financial results for the quarter and full financial year ending March 31, 2026. This is a routine compliance filing under SEBI's Insider Trading Regulations, meaning designated employees, their relatives, and connected persons cannot buy or sell Mankind Pharma shares during this period. The exact date of the board meeting to approve the Q4 and FY26 results has not yet been disclosed and will be communicated later. The window typically reopens 48 hours after results are published.
No direct impact on retail shareholders or stock price. This is a standard pre-results compliance measure that signals the company's Q4 and FY26 earnings announcement is approaching, which could be a key catalyst for the stock.